Target Name: WDR46
NCBI ID: G9277
Review Report on WDR46 Target / Biomarker Content of Review Report on WDR46 Target / Biomarker
WDR46
Other Name(s): WD repeat domain 46, transcript variant 1 | WDR46 variant 2 | OTTHUMP00000178637 | FP221 | UTP7 | WD repeat domain 46 | BING4 | WD repeat-containing protein 46 | WD repeat-containing protein 46 (isoform 1) | WDR46_HUMAN | C6orf11 | WD repeat-containing protein BING4 | WD repeat-containing protein 46 (isoform 2) | WD repeat domain 46, transcript variant 2 | WDR46 variant 1

WDR46: A Potential Cancer Drug Target and Biomarker

WDR46 (Wnt-related gene 46) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. WDR46 is a key regulator of the Wnt signaling pathway, which plays a crucial role in the development and maintenance of tissues and organs during development and throughout life.

The Wnt signaling pathway is a well-established pathway that involves the interaction between various proteins and RNA molecules. It is involved in the regulation of cell proliferation, differentiation, and survival, and is implicated in numerous diseases, including cancer, neurodegenerative diseases, and developmental disorders.

WDR46 is a key regulator of the Wnt signaling pathway

WDR46 is a non-coding RNA molecule that is expressed in various tissues and cells of the body. It is a key regulator of the Wnt signaling pathway, which is involved in the regulation of cell proliferation, differentiation, and survival.

WDR46 functions as a negative regulator of the Wnt signaling pathway. It interacts with the protein 尾-catenin, which is a key component of the Wnt signaling pathway.尾-catenin is a transmembrane protein that is involved in the regulation of cell adhesion, and is a target of several anti-cancer drugs, including taxanes and vasodilators.

WDR46 functions as an inhibitor of the Wnt signaling pathway

WDR46 functions as an inhibitor of the Wnt signaling pathway. It interacts with 尾-catenin and inhibits the activity of 尾-catenin, which is involved in the regulation of cell proliferation and survival. This interaction between WDR46 and 尾-catenin makes it a potential drug target and biomarker for cancer.

WDR46 is a potential drug target for cancer

WDR46 is a potential drug target for cancer, due to its involvement in the regulation of the Wnt signaling pathway. Several studies have suggested that inhibitors of WDR46 may be effective in treating various cancers, including breast, ovarian, and colorectal cancers.

One of the reasons for the potential of WDR46 as a cancer drug is its involvement in the regulation of cell proliferation and survival. Cancer cells are characterized by uncontrolled cell proliferation, which is a key mechanism that allows cancer cells to grow and evolve. By inhibiting the Wnt signaling pathway, WDR46 may be able to inhibit the growth and survival of cancer cells.

Another potential mechanism by which WDR46 may be involved in cancer treatment is its role as a biomarker. Cancer cells often have different gene expression patterns than healthy cells, and these differences can be used as biomarkers for cancer diagnosis and treatment. WDR46 is a potential biomarker for cancer, due to its expression in various tissues and cells of the body.

Conclusion

In conclusion, WDR46 is a non-coding RNA molecule that is involved in the regulation of the Wnt signaling pathway. It is a potential drug target and biomarker for cancer, due to its involvement in the regulation of cell proliferation and survival. Further research is needed to fully understand the role of WDR46 in cancer biology and treatment.

Protein Name: WD Repeat Domain 46

Functions: Scaffold component of the nucleolar structure. Required for localization of DDX21 and NCL to the granular compartment of the nucleolus (PubMed:23848194). Part of the small subunit (SSU) processome, first precursor of the small eukaryotic ribosomal subunit. During the assembly of the SSU processome in the nucleolus, many ribosome biogenesis factors, an RNA chaperone and ribosomal proteins associate with the nascent pre-rRNA and work in concert to generate RNA folding, modifications, rearrangements and cleavage as well as targeted degradation of pre-ribosomal RNA by the RNA exosome (PubMed:34516797)

The "WDR46 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about WDR46 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

WDR47 | WDR48 | WDR49 | WDR5 | WDR53 | WDR54 | WDR55 | WDR59 | WDR5B | WDR6 | WDR62 | WDR64 | WDR7 | WDR70 | WDR72 | WDR73 | WDR74 | WDR75 | WDR76 | WDR77 | WDR81 | WDR82 | WDR82P1 | WDR83 | WDR83OS | WDR86 | WDR86-AS1 | WDR87 | WDR88 | WDR89 | WDR90 | WDR91 | WDR93 | WDR97 | WDSUB1 | WDTC1 | WEE1 | WEE2 | WEE2-AS1 | WFDC1 | WFDC10A | WFDC10B | WFDC11 | WFDC12 | WFDC13 | WFDC2 | WFDC21P | WFDC3 | WFDC5 | WFDC6 | WFDC8 | WFDC9 | WFIKKN1 | WFIKKN2 | WFS1 | WHAMM | WHAMMP1 | WHAMMP2 | WHAMMP3 | WHRN | WIF1 | WIPF1 | WIPF2 | WIPF3 | WIPI1 | WIPI2 | WIZ | WLS | WNK1 | WNK2 | WNK3 | WNK4 | Wnt | WNT1 | WNT10A | WNT10B | WNT11 | WNT16 | WNT2 | WNT2B | WNT3 | WNT3A | WNT4 | WNT5A | WNT5B | WNT6 | WNT7A | WNT7B | WNT8A | WNT8B | WNT9A | WNT9B | WRAP53 | WRAP73 | WRN | WRNIP1 | WSB1 | WSB2 | WSCD1 | WSCD2